Sugi Predict

Sugi Predict / Compounds / SCHEMBL19040355

SCHEMBL19040355

SCHEMBL19040355

CCOc1ncc(C)cc1S(=O)(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 1/20 0.40
▸ SLC13A5 Q86YT5 1/20 0.39
▸ ALPL P05186 4/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ PTGS2 P35354 1/20 0.36
▸ CA12 O43570 2/20 0.36
▸ CA1 P00915 2/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA9 Q16790 2/20 0.36
▸ CA14 Q9ULX7 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ TSHR P16473 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ APLNR P35414 1/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18601131 0.83 ALPL (0.41) TRPV4ALPLCA12CA1CA2
SCHEMBL30719557 0.83 TRPV4 (0.39) TRPV4SLC13A5ALPLPTGS2SMN1; SMN2
SCHEMBL22532403 0.83 TRPV4 (0.39) TRPV4SLC13A5ALPLPTGS2SMN1; SMN2
SCHEMBL20304553 0.82 ALPL (0.41) TRPV4ALPLCA12CA1CA2
SCHEMBL18601178 0.78 PTGS2 (0.42) MAPK1PTGS2L3MBTL1MEN1KMT2A
SCHEMBL19040387 0.78 HTT (0.35) SLC13A5PTGS2CA12CA1CA2
SCHEMBL19040397 0.75 PTGS2 (0.33) PTGS2
SCHEMBL25226442 0.74 APLNR (0.35) TRPV4PTGS2KMT2AAPLNR
SCHEMBL21713598 0.73 ALDH1A1 (0.38) TRPV4KMT2AAPLNRMAPTRORC
SCHEMBL12037978 0.73 SLC13A5 (0.40) SLC13A5MAPK1L3MBTL1HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180208587-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2018-07-26 — — US disclosed
US-9896441-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2018-02-20 — — US disclosed
US-20170183331-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170183331-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORA, RORB, RORC TRPV4 799/4885SLC13A5 4237/4885ALPL 4461/4885
US-20180208587-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORA, RORB, RORC TRPV4 799/4885SLC13A5 4237/4885ALPL 4461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.